pannarin: photoirradiation of above cpd leads to its decomposition which is reduced by oxygen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
pannarin : A member of the class of depsidones that is 11H-dibenzo[b,e][1,4]dioxepine substituted by methyl groups at positions 1,6 and 9, chloro group at position 2, hydroxy group at position 3, formyl group at position 4, methoxy group at position 8 and an oxo group at position 11. It is a lichen metabolite isolated from several Psoroma species. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 162780 |
| CHEMBL ID | 285415 |
| CHEBI ID | 144185 |
| MeSH ID | M0226548 |
| Synonym |
|---|
| NSC646008 , |
| 2-chloro-3-hydroxy-8-methoxy-1,6,9-trimethyl-11-oxo-11h-dibenzo[b,e][1,4]dioxepine-4-carbaldehyde |
| 8-chloro-9-hydroxy-3-methoxy-1,4,7-trimethyl-6-oxo-benzo[b][1,4]benzodioxepine-10-carbaldehyde |
| NCI60_015821 |
| nsc-646008 |
| pannarin |
| CHEMBL285415 , |
| bdbm50056915 |
| CHEBI:144185 |
| pannarine |
| 55609-84-2 |
| 11h-dibenzo(b,e)(1,4)dioxepin-4-carboxaldehyde, 2-chloro-3-hydroxy-8-methoxy-1,6,9-trimethyl-11-oxo- |
| DTXSID50204157 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The treatment with pannarin produces bactericidal activity without significant calcein release, consistent with lack of lysis or even significant structural damage to the cytoplasmic membrane." | ( In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates. Amicosante, G; Bellio, P; Brisdelli, F; Celenza, G; Garbarino, JA; Nicoletti, M; Perilli, M; Piovano, M; Segatore, B; Setacci, D, 2012) | 0.97 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The in vitro antimicrobial activities of pannarin, a depsidone isolated from lichens, collected in several Southern regions of Chile (including Antarctica), was evaluated alone and in combination with five therapeutically available antibiotics, using checkerboard microdilution assay against methicillin-resistant clinical isolates strains of Staphylococcus aureus." | ( In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates. Amicosante, G; Bellio, P; Brisdelli, F; Celenza, G; Garbarino, JA; Nicoletti, M; Perilli, M; Piovano, M; Segatore, B; Setacci, D, 2012) | 0.92 |
| Role | Description |
|---|---|
| lichen metabolite | Any metabolite that is produced during a metabolite reaction in lichens (composite organisms consisting of a fungus and a photosynthetic partner co-existing in a symbiotic relationship). |
| apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| depsidones | Any organic heteropolycyclic compound based on a tricyclic diphenyl ether lactone system and its substituted derivatives thereof. |
| organic heterotricyclic compound | An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. |
| aldehyde | A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group. |
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Integrase | Human immunodeficiency virus 1 | IC50 (µMol) | 4.0167 | 0.0005 | 1.5443 | 10.0000 | AID93680; AID93700; AID93702; AID93703; AID93705; AID93707 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID93705 | Inhibitory concentration of compound against strand transfer of HIV-1 integrase in experiment 1 | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| AID91561 | Percentage inhibition of compound against 3'-processing of HIV-1 integrase at 100 ug/mL | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| AID93702 | Inhibitory concentration of compound against 3'-processing of HIV-1 integrase in experiment 2 | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| AID93707 | Inhibitory concentration of compound against strand transfer of HIV-1 integrase in experiment 2 | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| AID91562 | Percentage inhibition against strand transfer of HIV-1 integrase at 100 ug/mL | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| AID93703 | Inhibitory concentration of compound against disintegration (reversal of strand transfer)of HIV-1 integrase | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| AID93680 | Inhibitory activity against HIV-1 integrase | 2004 | Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6 | HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. |
| AID93700 | Inhibitory concentration of compound against 3'-processing of HIV-1 integrase in experiment 1 | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (72.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||